•
TR
TRVI
Trevi Therapeutics, Inc. Common Stock
yahooPHARMACEUTICAL PREPARATIONS
--
Price Chart
Market Cap
1.32B
Volume
1.00M
52W High
$14.39
52W Low
$3.47
Open
$0.00
Prev Close
$10.42
Day Range
0.00 - 0.00
About Trevi Therapeutics, Inc. Common Stock
Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis, or IPF, and other chronic cough indications, and for the treatment of prurigo nodularis. Haduvio is an oral extended-release formulation of nalbuphine.
Latest News
Chronic Refractory Cough Market is Expected to Boom by 2034 Driven by Advancements in Treatment Options | DelveInsight
GlobeNewswire Inc.•Nov 24
TRVI STOCKHOLDER ALERT: Kaskela Law LLC Announces Investigation of Trevi Therapeutics, Inc. (NASDAQ: TRVI) and Encourages Long-Term Investors to Contact the Firm
GlobeNewswire Inc.•Jun 26
Pulmonary Fibrosis Clinical Trial Pipeline Appears Robust With 110+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight
GlobeNewswire Inc.•Jan 28
Trevi Therapeutics (TRVI) Could Find a Support Soon, Here's Why You Should Buy the Stock Now
Zacks Investment Research•Apr 18
Why Trevi Therapeutics (TRVI) Stock Might be a Great Pick
Zacks Investment Research•Apr 4
Trevi Therapeutics, Inc. (TRVI) Upgraded to Strong Buy: Here's Why
Zacks Investment Research•Jan 17
The Russell 2000 Index has soared, but you might be better off looking elsewhere for quality small-cap stocks
MarketWatch•Jan 6
Trevi Therapeutics, Inc. (TRVI) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?
Zacks Investment Research•Nov 14